ITOS(Delisted)
iTeos Therapeutics·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ITOS
Iteos Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing immuno-oncology therapeutics for cancer
321 Arsenal St
, Watertown
, MA 02472
--
ITeos Therapeutics, Inc. was incorporated under the laws of the State of Delaware on October 4, 2019. The company is a clinical-stage biopharmaceutical company that has pioneered the discovery and development of a new generation of highly differentiated immuno-oncology therapies for patients. The company uses their deep understanding of the tumor microenvironment and immunosuppressive pathways to design new drug candidates with the goal of improving the clinical efficacy of tumor therapy.
Company Financials
EPS
ITOS has released its 2025 Q2 earnings. EPS was reported at -1.81, versus the expected -0.82, missing expectations. The chart below visualizes how ITOS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
